Celgene Corp. (CELG)

94.69
1.00 1.10
NASDAQ : Health Technology
Prev Close 95.71
Open 95.65
Day Low/High 94.70 / 96.05
52 Wk Low/High 58.59 / 98.97
Volume 1.94M
Avg Volume 4.01M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 67.81B
EPS 5.70
P/E Ratio 13.11
Div & Yield N.A. (N.A)

Latest News

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.

Celgene Reports Second Quarter 2019 Operating And Financial Results

Celgene Reports Second Quarter 2019 Operating And Financial Results

Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

What to Watch for Earnings In the Second Half of 2019

What to Watch for Earnings In the Second Half of 2019

Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.

Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses

Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses

Bristol-Myers Squibb posts stronger-than-expected second-quarter earnings and boost its full-year profit forecast while adding that its $74 billion acquisition of Celgene would likely close in early 2020.

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.

Celgene And The Multiple Sclerosis Association Of America Bring MS MindShift Initiative And "Brain Bulb" Hot Air Balloon To Festival To Raise Awareness Of Multiple Sclerosis And Brain Health

Celgene And The Multiple Sclerosis Association Of America Bring MS MindShift Initiative And "Brain Bulb" Hot Air Balloon To Festival To Raise Awareness Of Multiple Sclerosis And Brain Health

Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative to the 37 th Annual QuickChek New Jersey Festival of Ballooning in Readington, NJ, on July 26-28, where...

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.

FDA Approves OTEZLA® (apremilast) For The Treatment Of Oral Ulcers Associated With Behçet's Disease

FDA Approves OTEZLA® (apremilast) For The Treatment Of Oral Ulcers Associated With Behçet's Disease

Celgene Corporation (NASDAQ:CELG) today announced that the U.S.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks end little changed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Squibb slumped to the bottom of the S&P 500 Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

U.S. stocks look set to test all time highs again Monday, following a third consecutive weekly gain for all three benchmarks on Wall Street, as investors continue to bet that central bank support will boost global equities and this weekend's G20 Summit in Osaka will trigger a breakthrough in U.S.-China trade talks.

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG).

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Winner selected for potential of innovation to impact people with multiple sclerosis (MS) and their care partners

TheStreet Quant Rating: C+ (Hold)